Navigation Links
Organovo Reports Q3 2012 Financial Results, Provides Business Update
Date:11/16/2012

ent. Organovo's bioprinting technology can also be developed to create surgical tissues for direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

 Organovo Holdings Inc.(A development stage company)Condensed Consolidated Balance Sheets September 30, 2012 December 31, 2011 (Unaudited)(Audited)AssetsCurrent AssetsCash and cash equivalents$
7,675,918

$
339,607Grants receivable

95,477

—Inventory312,182

291,881Deferred financing costs—

318,843Prepaid expenses and other current assets144,515

'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
7. Organovo To Present At Lazard Healthcare Conference
8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
10. Interleukin Genetics Reports Third Quarter 2011 Financial Results
11. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Tetrahedral dice, which have four triangular sides, pack ... to research performed by a collaboration of New York ... result of a series of experiments that involved pouring ... dice until the containers were completely filled. After adding ...
... 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ( ANPI, TSX: ANP), a specialty ... exclusive distribution agreement with B. Braun for its proprietary Quill(TM) SRS product line ... The term of the distribution agreement will be for five years. , ... According to The Royal College of Surgeons ...
... , LAWRENCEVILLE, N.J. , May 3 ... (n = 520) multi-center patient registry study of its Lacrisert® ... index (OSDI) in patients with moderate-to-severe dry eye after one ... poster this week during the 2010 Annual Meeting of the ...
Cached Biology Technology:Densest dice packing and computing with molecules 2Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 2Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 3Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 4Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 5Study of Lacrisert(R) Dry Eye Insert 2Study of Lacrisert(R) Dry Eye Insert 3Study of Lacrisert(R) Dry Eye Insert 4Study of Lacrisert(R) Dry Eye Insert 5
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Tall fescue toxicosis is one of the most ... no cure for this costly disorder, there are proven ... new professional guide, Tall Fescue Toxicosis and Management is ... want to better understand and control toxicosis. "We ...
... NY, June 15 Robert H. Wurtz, PhD, a pioneer ... of the 2010 Neuroscience Prize of The Peter and Patricia ... information and controls eye movements laid the groundwork for subsequent ... led scientists to a deeper understanding of how the brain ...
... of dedicated South Florida researchers from the University of ... and the National Oceanic and Atmospheric Administration,s Atlantic Oceanographic ... whether oil was, as predicted, being pulled into the ... The University of Miami,s 96-foot catamaran ...
Cached Biology News:Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 2Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 3Scientists locate oil plume extending toward Dry Tortugas 2Scientists locate oil plume extending toward Dry Tortugas 3
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: